Literature DB >> 27829661

Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction.

Takuji Tomimatsu1, Kazuya Mimura1, Masayuki Endo1, Keiichi Kumasawa1, Tadashi Kimura1.   

Abstract

Preeclampsia is a systemic vascular disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. This condition targets several organs, including the kidneys, liver and brain, and is the leading cause of maternal and perinatal morbidity and mortality. Furthermore, recent evidence has revealed preeclampsia as a significant risk factor for future cardiovascular diseases in these women. Over the past decade, increasing evidence has indicated that maternal angiogenic imbalances caused by placental antiangiogenic factors play a central role in the systemic vascular dysfunction underling preeclampsia. The severity of the maternal antiangiogenic state correlates closely with maternal and perinatal outcomes. Assessing angiogenic imbalance and several vascular function tests have also emerged as a way of detecting systemic vascular dysfunction during pregnancy. This review summarizes the current understanding of the pathophysiology of preeclampsia, its clinical applications and clinical evidence for future cardiovascular risks.

Entities:  

Mesh:

Year:  2016        PMID: 27829661     DOI: 10.1038/hr.2016.152

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  117 in total

1.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Soluble endoglin contributes to the pathogenesis of preeclampsia.

Authors:  Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi
Journal:  Nat Med       Date:  2006-06-04       Impact factor: 53.440

3.  Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.

Authors:  Alfredo Leaños-Miranda; Inova Campos-Galicia; María Guadalupe Berumen-Lechuga; Carlos José Molina-Pérez; Yolanda García-Paleta; Irma Isordia-Salas; Karla Leticia Ramírez-Valenzuela
Journal:  J Rheumatol       Date:  2015-05-15       Impact factor: 4.666

4.  Central aortic blood pressure and augmentation index during normal pregnancy.

Authors:  Mika Fujime; Takuji Tomimatsu; Yuko Okaue; Shinsuke Koyama; Takeshi Kanagawa; Takeshi Taniguchi; Tadashi Kimura
Journal:  Hypertens Res       Date:  2012-02-02       Impact factor: 3.872

5.  Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.

Authors:  Jeffrey S Gilbert; Joseph Verzwyvelt; Drew Colson; Marietta Arany; S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

6.  Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia.

Authors:  Kazuya Mimura; Takuji Tomimatsu; Namuxila Sharentuya; Ekaterine Tskitishvili; Yukiko Kinugasa-Taniguchi; Takeshi Kanagawa; Tadashi Kimura
Journal:  Am J Obstet Gynecol       Date:  2010-03-11       Impact factor: 8.661

Review 7.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

Review 8.  Pre-eclampsia part 1: current understanding of its pathophysiology.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

9.  Maternal hemodynamics at 11-13 weeks' gestation and risk of pre-eclampsia.

Authors:  A Khalil; R Akolekar; A Syngelaki; M Elkhouli; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2012-06-18       Impact factor: 7.299

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  31 in total

1.  Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy.

Authors:  Michele K Saums; Caroline C King; Jenna C Adams; Anandi N Sheth; Martina L Badell; Marisa Young; Lynn M Yee; Ellen G Chadwick; Denise J Jamieson; Lisa B Haddad
Journal:  Obstet Gynecol       Date:  2019-12       Impact factor: 7.661

2.  Impairment of BKca channels in human placental chorionic plate arteries is potentially relevant to the development of preeclampsia.

Authors:  Mengzhou He; Fanfan Li; Meitao Yang; Yao Fan; Rajluxmee Beejadhursing; Yin Xie; Yuan Zhou; Dongrui Deng
Journal:  Hypertens Res       Date:  2017-11-16       Impact factor: 3.872

3.  Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia.

Authors:  Jennifer L Sones; Audrey A Merriam; Angelina Seffens; Dex-Ann Brown-Grant; Scott D Butler; Anna M Zhao; Xinjing Xu; Carrie J Shawber; Jennifer K Grenier; Nataki C Douglas
Journal:  FASEB J       Date:  2018-01-08       Impact factor: 5.191

4.  LncRNA CRNDE regulates trophoblast cell proliferation, invasion, and migration via modulating miR-1277.

Authors:  Hua Zhu; Li Kong
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.

Authors:  Dorien Reijnders; Chin-Chi Liu; Xinjing Xu; Anna M Zhao; Kelsey N Olson; Scott D Butler; Nataki C Douglas; Jenny L Sones
Journal:  Physiol Genomics       Date:  2018-03-09       Impact factor: 3.107

Review 6.  Management of Maternal Stroke and Mitigating Risk.

Authors:  Mariel G Kozberg; Erica C Camargo
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-21

7.  An autophagic deficit in the uterine vessel microenvironment provokes hyperpermeability through deregulated VEGFA, NOS1, and CTNNB1.

Authors:  Bora Lee; Hyejin Shin; Ji-Eun Oh; Jaekyoung Park; Mira Park; Seung Chel Yang; Jin-Hyun Jun; Seok-Ho Hong; Haengseok Song; Hyunjung Jade Lim
Journal:  Autophagy       Date:  2020-06-17       Impact factor: 16.016

8.  Elevated Serum SFRP5 Levels During Preeclampsia and Its Potential Association with Trophoblast Dysfunction via Wnt/β-Catenin Suppression.

Authors:  Yi Zhang; Yuxin Ran; Yunpeng Ma; Hua Huang; Ying Chen; Hongbo Qi
Journal:  Reprod Sci       Date:  2021-08-11       Impact factor: 3.060

Review 9.  The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis.

Authors:  Ioannis Bellos; Vasilios Pergialiotis; Dimitrios Loutradis; Georgios Daskalakis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-04-27       Impact factor: 3.738

10.  Magnesium sulfate prophylaxis attenuates the postpartum effects of preeclampsia by promoting M2 macrophage polarization.

Authors:  Xiaolan Li; Li Li; Li Tao; Honghui Zheng; Meiguo Sun; Yueran Chen; Yuanhua Chen; Yuanyuan Yang
Journal:  Hypertens Res       Date:  2020-07-27       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.